eDiagnosis(SZ:002932) Sou Hu Cai Jing·2025-06-03 09:12Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Mingde Biological Technology Co., Ltd., particularly its stock performance and industry comparison [1][2] - As of June 3, the closing price of Mingde Biological was 19.71 yuan, with a PE ratio of 118.10, marking a new low in 111 days, and a total market capitalization of 4.583 billion yuan [1] - The average PE ratio for the medical device industry is 50.80, with a median of 36.71, positioning Mingde Biological at the 108th rank within the industry [1][2] Group 2 - As of April 18, 2025, the number of shareholders for Mingde Biological was 25,248, a decrease of 345 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of the company includes the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as solutions for critical care information and third-party medical testing services [1] - In the latest quarterly report for Q1 2025, the company reported a revenue of 69.96 million yuan, a year-on-year increase of 14.76%, but a net loss of approximately 3.66 million yuan, representing a year-on-year decline of 111.43%, with a gross profit margin of 16.37% [1]